KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Treasury Shares (2021 - 2025)

Rigel Pharmaceuticals has reported Treasury Shares over the past 5 years, most recently at $607621.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $607621.0 for Q4 2025, up 56.89% from a year ago — trailing twelve months through Dec 2025 was $607621.0 (up 56.89% YoY), and the annual figure for FY2025 was $607621.0, up 56.89%.
  • Treasury Shares for Q4 2025 was $607621.0 at Rigel Pharmaceuticals, up from $569106.0 in the prior quarter.
  • Over the last five years, Treasury Shares for RIGL hit a ceiling of $4.1 million in Q1 2024 and a floor of $185938.0 in Q4 2023.
  • Median Treasury Shares over the past 5 years was $607621.0 (2025), compared with a mean of $1.1 million.
  • Biggest five-year swings in Treasury Shares: skyrocketed 387.8% in 2022 and later tumbled 86.05% in 2025.
  • Rigel Pharmaceuticals' Treasury Shares stood at $226250.0 in 2021, then surged by 387.8% to $1.1 million in 2022, then plummeted by 83.15% to $185938.0 in 2023, then surged by 108.29% to $387282.0 in 2024, then skyrocketed by 56.89% to $607621.0 in 2025.
  • The last three reported values for Treasury Shares were $607621.0 (Q4 2025), $569106.0 (Q3 2025), and $565846.0 (Q2 2025) per Business Quant data.